Table 3.

Univariate analysis of overall survival to 101cases of SCLC patients with brain metastases.

Factor	Total (n = 101)	Median survival time (month)	P value
sex			0.146
male	73	16.75 ± 9.24
female	28	18.79 ± 13.93
age			0.375
<65	84	17.11 ± 10.77
≥ 65	17	18.56 ± 10.97
PS score			0.049
1	96	18.38 ± 11.27
2	5	12.62 ± 7.74
stage			0.001
Local stage	57	20.55 ± 11.37
extensive stage	44	13.17 ± 8.23
Baseline blood sodium			0.918
normal	79	17.61 ± 9.10
low	22	18.56 ± 10.97
Baseline NSE			0.028
normal	28	21.23 ± 14.02
high	73	15.97 ± 8.86
Different treatment patterns			0.003
brain radiotherapy combined with sequential chemotherapy group	32	21.03 ± 12.76
chemotherapy combined with sequential brain radiotherapy group	16	19.69 ± 8.92
brain radiotherapy group	32	15.86 ± 10.43
chemotherapy group	21	12.07 ± 5.80
Whether brain metastasis during initial treatment			0.000
with	28	10.59 ± 5.26
without	73	19.90 ± 11.16
Whether chemotherapy when brain metastasis			0.017
yes	54	19.51 ± 11.11
no	47	14.45 ± 9.55
Focus number of brain metastases			0.395
<3	19	19.21 ± 10.60
≥ 3	82	16.88 ± 10.75